RVMD ▲ +0.7% - Revolution Medicines, Inc. $RVMD - Revolution Medicines Begins Treating Patients in Phase 3 RASolve 308 Trial Evaluating Zoldonrasib in Combination with Pembrolizumab and Chemotherapy as First-Line Treatment for Patients with Metastatic RAS G12D Non-Squamous Non-Small Cell Lung Cancer 20-OCT-2026 08:00 AM ET